The FDA joined Massachusetts officials in a surprise inspection of an unnamed pharmacy similar to the New England Compounding Center, which was tied to a national fungal meningitis outbreak. "The FDA has authority over certain things and if they feel this registrant is performing business practices in their domain, that's their call," said Dr. Madeleine Biondolillo, director of the state's Bureau of Health Care Safety and Quality. Cease-and-desist orders have been issued to at least four drug compounders since the start of the surprise inspections.

Related Summaries